Connect with us

Hi, what are you looking for?

Jewish Business News


Teva Receives FDA Approval For Leukemia Treatment For Injection

Synribo received provisional approval in 2012 subject to additional clinic trial data.
Synribo ,    TEVA,    Injection. Niddel
 Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Synribo  (omacetaxine mepesuccinate) for injection.
This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.
Synribo  is indicated for adult patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).“With this approval, based on the final analysis of two Phase II trials that evaluated efficacy and tolerability data of Synribo , we believe healthcare providers can be even more confident in the clinical profile of this important medicine, ” said Rob Koremans, M.D., President and CEO, Global Specialty Medicines. “This approval reinforces our ongoing commitment to providing Synribo to people living with CML who have failed two or more TKI therapies.“  



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.